EU/3/05/332: Orphan designation for the treatment of acute myeloid leukaemia

1,2-Bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine

Table of contents

Overview

On 14 December 2005, orphan designation (EU/3/05/332) was granted by the European Commission to Vion (UK) Limited, United Kingdom, for 1,2-bi (methylsulphonyl)-1-(2-chloroethyl)-2- [(methylamino)carbonyl]hydrazine for the treatment of acute myeloid leukaemia.

Key facts

Active substance
1,2-Bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine
Intended use
Treatment of acute myeloid leukaemia
Orphan designation status
Positive
EU designation number
EU/3/05/332
Date of designation
14/12/2005
Sponsor
Vion (UK) Limited
℅ i3 Research
Sygnus Court
22-32 Market Street
Maidenhead SL6 8AD
United Kingdom
Tel. +44 (0)1628 408408
Fax +44 (0)1628 408401
E-mail: vionuk@vionpharm.co.uk

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating